Clinical trials: AI
Type 1 Diabetes Mellitus With Hypoglycemia
DailyDose Smart Snack Study for T1D on MDI
This is a single-center, open-label, crossover trial with two arms and two periods (2x2) and one-week washout period. The study is designed to evaluate the efficacy of an AI-based bedtime smart snack intervention in reducing…
- Trial name
- NCT05967260
- Testing
- DailyDose Smart Snack app, Dexcom G6 CGM
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Oregon Health and Science University
Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
Study to evaluate the safety, tolerability, antitumor activity, and pharmacology of MEDI-573 in combination with an aromatase inhibitor (AI) in adult subjects with HR+, HER2-negative MBC.
- Trial name
- NCT01446159
- Testing
- MEDI-573, Aromatase Inhibitor
- Where
- 71 sites in United States, Belgium and 9 more
- Volunteers
- 188 people
- Sponsor
- MedImmune LLC
Diabetic Retinopathy, Diabetic Macular Edema
Bangladesh PRODUCTIVity in Eyecare Trial
The purpose of this study is to assess the impact of using autonomous artificial intelligence (AI) system for identification of diabetic retinopathy (DR) and diabetic macular edema on productivity of retina specialists in…
- Trial name
- B-PRODUCTIVE (NCT05182580)
- Testing
- Results utilized from autonomous AI diagnostic system for diabetic retinopathy and/or diabetic macular edema
- Where
- Bangladesh
- Volunteers
- 993 people, healthy volunteers welcome
- Sponsor
- Orbis
Medication Adherence
Managing Insulin With a Voice AI
This study randomizes participants to have their basal insulin titrated either through standard of care or by receiving prompts through interactions with an AI-enabled smart speaker device.
- Trial name
- MIVA (NCT05081011)
- Testing
- Voice Assistant Device
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Stanford University
Cancer
Assessing the Performance of Artificial Intelligence (AI)-Augmented Electronic Health Record (EHR) Data Abstraction for Clinical Trial Patient Screening
Identifying eligible patients is a key process in the clinical trial enterprise. Currently, this process relies on time-intensive manual chart review, creating a rate-limiting step for trial participation.
- Trial name
- NCT06561217
- Testing
- Chart review
- Where
- 2 sites in United States
- Volunteers
- 355 people
- Sponsor
- University of Pennsylvania
Estrogen Receptor Positive, HER2/Neu Negative
FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer
This clinical trial studies fluorine F 18 fluorothymidine (FLT) positron emission tomography (PET) in measuring treatment response in patients with newly diagnosed estrogen receptor (ER)-positive, human epidermal growth factor…
- Conditions
- Estrogen Receptor Positive, HER2/Neu Negative, Male Breast Carcinoma, Stage IA Breast Cancer
- Trial name
- NCT01928186
- Testing
- Fluorothymidine F-18, Positron Emission Tomography, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Washington
Breast Cancer
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- NCT00382070
- Testing
- Letrozole
- Where
- 806 sites in United States, Canada and 1 more
- Volunteers
- 3,966 people
- Sponsor
- NSABP Foundation Inc
Cystic Fibrosis
Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis (CF) Patients With Pseudomonas Aeruginosa (PA)
The purpose of this study was to evaluate the safety and efficacy of multiple courses of AZLI in patients with cystic fibrosis (CF) and lung infection due to Pseudomonas aeruginosa (PA).
- Trial name
- AIR-CF3 (NCT00128492)
- Testing
- AZLI 75 mg two times a day (BID)/ three times a day (TID)
- Where
- 65 sites in United States, Australia and 2 more
- Volunteers
- 274 people
- Sponsor
- Gilead Sciences
Cognitive Ability, General, High Blood Pressure
Assessing the Impact of Calcium Channel Blockers on COGnitive Function in the Very Elderly (AI-COG)
Older adults are at increased risk of high blood pressure and cognitive decline. High blood pressure itself also increases risk of cognitive decline.
- Trial name
- NCT01868165
- Where
- 7 sites in United Kingdom
- Volunteers
- 337 people
- Sponsor
- Imperial College London
ER+ Breast Cancer
Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing
The addition of entinostat to an AI will result in a maximal abrogation of estrogen receptor-α mediated activity and inhibit mechanisms of resistance to the aromatase inhibitor.
- Trial name
- NCT00828854
- Testing
- Entinostat, Aromatase Inhibitor (AI) Therapy
- Where
- 6 sites in Ireland, United Kingdom
- Volunteers
- 27 people
- Sponsor
- Syndax Pharmaceuticals
Breast Cancer
A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.
The purpose of this study is to describe the effect of the medicine palbociclib when given together with an aromatase inhibitor for treatment of breast cancer.
- Trial name
- NCT06307457
- Testing
- Palbociclib in combination with AI
- Where
- Denmark
- Volunteers
- 604 people
- Sponsor
- Pfizer
Physician Workflow, Artificial Intelligence (AI)
A Randomized Controlled Trial of Ambient Artificial Intelligence Scribe Technologies
This is a three-arm pragmatic RCT of 238 outpatient physicians at a large academic health system, randomized 1:1:1 to one of two AI scribe tools or a usual-care control group.
- Trial name
- AIScribe RCT (NCT06792890)
- Testing
- Use Nabla AI Scribe tool provided, Use AI Scribe tool provided by Vendor B
- Where
- United States
- Volunteers
- 238 people
- Sponsor
- University of California, Los Angeles
Relief of Joint Pain
Vitamin B12 for Aromatase Inhibitors Musculoskeletal Symptoms
Significant Aromatase Inhibitor-associated toxicity, affects as many as 50% of patients with breast cancer leading to early discontinuation of this life-saving cancer treatment.
- Trial name
- NCT03069313
- Testing
- Vitamin B12
- Volunteers
- 41 people
- Sponsor
- Texas Tech University Health Sciences Center, El Paso
Metastatic Breast Cancer
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
This study was a multicenter, randomized, double-blind, placebo-controlled Phase III study to determine the efficacy and safety of treatment with Buparlisib plus Fulvestrant vs.
- Trial name
- BELLE-3 (NCT01633060)
- Testing
- Fulvestrant, BKM120
- Where
- 197 sites in United States, Argentina and 20 more
- Volunteers
- 432 people
- Sponsor
- Novartis Pharmaceuticals
Well Child Visit, Gaps in Care
A Trial of AI-Powered Text Message Outreach on Well-Child Visit Completion
The goal of this clinical trial is to evaluate whether conversational AI-powered text message outreach with appointment scheduling assistance improves well-child visit completion rates in Medicaid-enrolled children aged 0-21…
- Trial name
- HEDIS (NCT06698640)
- Testing
- Automated SMS, Automated SMS + Conversational AI Scheduling Assistance, Traditional Passive Outreach
- Where
- United States
- Volunteers
- 2,821 people
- Sponsor
- Waymark
Hypercholesterolaemia
Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Primary Objective: To collect real-use (usability) data assessing the robustness and user interaction of the new alirocumab auto-injector device (which is referred to as SYDNEY), in unsupervised settings.
- Trial name
- NCT03415178
- Testing
- Alirocumab SAR236553, Current auto-injector device (AI), New auto-injector device (SYDNEY)
- Where
- 13 sites in United States
- Volunteers
- 69 people
- Sponsor
- Sanofi
Breast Cancer
Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score
The purpose of this study is to see whether adding everolimus to hormone treatment before breast surgery will increase the chances of shrinking the breast cancer in those patients with hormone-responsive breast cancer and a lower…
- Trial name
- NCT02236572
- Testing
- Everolimus
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Yale University
Psychosis, Schizophrenia
CBTpro: Scaling up CBT for Psychosis Using Simulated Patients and Spoken Language Technologies
The primary objective of this grant is to develop and evaluate an Artificial Intelligence-based clinical training tool--CBTpro--to support high-quality skills training in CBT for psychosis (CBTp).
- Conditions
- Psychosis, Schizophrenia, Schizo Affective Disorder, Bipolar Disorder
- Trial name
- CBTpro (NCT05127837)
- Testing
- CBTpro
- Where
- 13 sites in United States
- Volunteers
- 601 people
- Sponsor
- University of Washington
Alzheimer Disease, Dementia
CONFIDENCE-AI Financial Education for Caregivers (CONFIDENCE-AI)
The intervention being tested, CONFIDENCE-AI is a refined version of the original CONFIDENCE intervention made to reduce psychological financial strain and improve management of out-of-pocket care costs while increasing caregiver…
- Conditions
- Alzheimer Disease, Dementia, Caregiver Burden, Financial Stress
- Trial name
- CONFIDENCE-AI (NCT06134180)
- Testing
- CONFIDENCE-AI
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Case Western Reserve University
Breast Cancer
HR+/ HER2- Advanced/ Metastatic Breast Cancer Real World Treatment Patterns and Outcomes
This is a retrospective, observational study that will document the treatment patterns and clinical outcomes of patients diagnosed with HR+/HER2- A/MBC who received CDK4/6i combination therapy with aromatase inhibitors (AI) as…
- Trial name
- NCT04396626
- Where
- United States
- Volunteers
- 975 people
- Sponsor
- Pfizer